Eli Lilly announces the successful Phase I study of the combination of Tirzepatide and Yiqizhu monoclonal antibody
On February 18, 2026, Lilly announced that the milestone TOGETHERPS0 open label Phase 1b study had achieved positive results. This study evaluated the efficacy of the combination of Yiqizhumab and Tilpotide in the treatment of moderate to severe plaque psoriasis with obesity or overweight (and at least one weight related complication) in adult patients treated with Yiqizhumab monotherapy. A total of 274 subjects were randomly assigned in a 1:1 ratio to receive subcutaneous injection treatment with either monotherapy with Yiqizhumab or in combination with Telopotide. Both groups of patients received guidance on a low calorie diet and increased physical activity. The main objective of the study is to evaluate the proportion of subjects who achieved PAS1100 at week 36 and experienced a weight loss of ≥ 10%. The subject's BMI must be ≥ 30 kg/m, or ≥ 27 to<30 kg/m2, and accompanied by at least one weight related complication.
The research results showed that at week 36, combination therapy achieved the primary endpoint and all key secondary endpoints, and was significantly better than monotherapy with Yiqizhumab in terms of skin clearance rate and weight loss. In the United States, approximately 61% of psoriasis patients are obese or overweight with at least one weight related comorbidity, highlighting the need for comprehensive treatment options that can comprehensively address the disease burden.
Tirzepatide Lyophilized Powder
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablets
(3)Injection
(4)Capsules
(5)Oral Drops
(6)Spray
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: KP-2-1/001
Tirzepatide CAS 2023788-19-2
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide Tirzepatide Lyophilized Powder, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/news/peptides-price-list-of-bloom-tech-85355837.html
Novo Nordisk CagriSema's head to head weight loss study with tilboptide did not reach the primary endpoint during the first phase of the study
On February 23, 2026, Novo Nordisk announced that the weight loss phase I REDEFINE 4 study of CagriSema compared to tilboptin did not reach the primary endpoint.
Cagr1Sema is a combination drug developed by Novo Nordisk, which includes the long-acting amylin analogue Cagrlintide and the GLP-1 receptor agonist, metformin. In December 2025, this compound has been declared for market in the United States, with the declared indications being: to reduce weight and maintain weight loss in the long term on the basis of reducing calorie intake and increasing physical activity, suitable for adults who are obese (BMI ≥ 30kg/m2) or overweight (BMI ≥ 27kg/m2) and have ≥ 1 weight related complication. It is expected that the FDA will make an approval decision on the marketing application by the end of 2026.
REDEFINE4 is an open label clinical trial lasting 84 weeks, involving 809 obese patients with at least one obesity related comorbidity. The aim is to evaluate the efficacy and safety of CagriSema (2.4mg+2.4mg) compared to Telopotide (15mg). The baseline average weight of the patient was 114.2kg. After completing the treatment analysis, the weight of the CagriSema group and the tirizin group decreased by 23.0% and 25.5%, respectively, after 84 weeks; According to intention to treat analysis, the weight loss of the two groups was 20.2% and 23.6%, respectively, and the study ultimately did not reach the non inferiority primary endpoint.
First, we will collaborate with Pfizer China to accelerate the commercialization process of GLP-1 with a bias towards it
On February 24, 2026, Pfizer and Xianweida Biotechnology announced that they had reached a commercial strategic cooperation agreement on the new generation of GLP-1 receptor agonist Ecn0gLutide injection (hereinafter referred to as Ecn0gLutide injection).
According to the agreement, Pfizer will obtain the exclusive commercial rights and interests of the product in Chinese Mainland, taking the first step in its strategic layout in the global metabolic field in China; At the same time, as the Marketing Authorization Holder (MAH) of the licensed product, Dahua Biotech is responsible for the research and development, registration, production, and supply of the licensed product. BioNTech will be entitled to receive a maximum payment of up to $495 million from Pfizer, including down payments, registration, and sales milestone payments.
Enoglutide is a new generation of cAMP biased GLP-1 receptor agonist independently developed by Xianweida Biology, which will provide more accurate treatment scheme for patients with type 2 diabetes and long-term weight management. With its unique biased mechanism, Enoglutide Injection has demonstrated excellent efficacy and safety in multiple clinical studies. The average weight loss of the Chinese population after placebo adjustment reached 15.1%, 92.8% of patients achieved clinically significant weight loss, and over 80% of patients met blood glucose standards (HbA1c<7.0%). Enoglutide injection has been approved by the National Drug Administration (NMPA) to be marketed for the treatment of adult type 2 diabetes in January 2026, and its application for marketing license of adult long-term weight management indications has been accepted by NMPA.
SGB-9768 (C3 siRNA) from Shengyin Biotechnology has been granted orphan drug qualification by the FDA once again
On February 24, 2026, Saint Yin Biotechnology, a clinical stage biotechnology company focused on innovative RNA interference (RNAi) therapy development, announced that its self-developed investigational drug SGB 9768 has been granted orphan drug status by the US Food and Drug Administration (FDA) for the treatment of immune complex mediated membranous proliferative glomerulonephritis (IC-MPGN).
IC-MPGN is a rare kidney disease, mainly caused by excessive activation of the complement system. The pathogenesis of this disease is complex and the course progresses rapidly, while traditional treatment options are limited. SGB-9768 is an sIRNA drug targeting complement C3, currently in phase I clinical trials. Its target indications include IC.MPGN, primary 1EA nephropathy (gAN), and C3 glomerulopathy (C3G), among other complement mediated kidney diseases. In the completed Phase 1 clinical trial, single subcutaneous administration of SGB-9768 achieved dose-dependent and significant daily sustained reduction in C3 levels and inhibition of complement pathway activity, demonstrating good safety and tolerability, and demonstrating its potential as the best in its class.
